Acute myeloid leukemia (AML) is the most common form of adult leukemia and has the lowest five-year overall survival rates of all blood cancers. Historically, AML treatment has been dominated by chemotherapy followed by allo-SCT in eligible patients. However, following a flurry of drug approvals since 2017, the AML treatment landscape is undergoing a transformation. The entry of novel agents into the treatment paradigm will enable the increasingly personalized treatment of patients, based on the characteristics of their disease and specific biomarkers. However, several areas of unmet need remain. Notably, patients unfit for intensive chemotherapy induction and relapsed/refractory AML patients offer significant commercial opportunity for innovative agents.
Label expansions and new drug approvals (e.g., venetoclax, FLT3 inhibitors) will fuel substantial growth of the AML therapy market over the 2018-2028 forecast period. This report provides insight on how treatment options for AML are likely to change over the 2018-2028 forecast period. It also analyzes the current and future earnings potential of AML therapies.
- How will first-generation FLT3 inhibitors (Rydapt) fare against second generation FLT3 inhibitors (Xospata, Vanflyta, crenolanib)? How do oncologists view this drug class? Which patient populations will be targeted?
- How will Venclexta and Daurismo perform in the sizeable and highly lucrative newly diagnosed patient population ineligible for intensive treatment?
- Will Mylotarg make a comeback in AML, despite its checkered approval history? How do oncologists currently view Mylotarg?
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Geographies: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 17 country-specific interviews with thought-leading hematologist-oncologists.
Epidemiology: Diagnosed incident cases of de novo AML and AML with MDS-related changes (we do no estimates cases of therapy-related AML). Clinically and market-relevant drug -treatable populations, including: First-line AML, younger patients (aged < 60); first-line AML, older patients (aged ≥ 60); second-line AML, younger patients (aged < 60); second-line AML, older patients (aged ≥ 60); third-line AML
Forecast: 10-year, annualized drug-level sales and patient shares of key AML therapies through 2028, segmented by brands/generics and drug-treatable populations .
Emerging therapies: Phase III: 8 drugs; Phase I/II: 10 drugs.